|
293 Companies |
|
490 Products |
|
490 Products |
|
199 Mechanisms of Action |
|
25 Trials |
|
7787 News |
|
| «12...4445464748495051525354...156157» |
- Enrollment closed: Effects of Gilenya (Fingolimod) on Thalamus Pathology and Cognitive Impairment in Patients With Relapsing Forms of Multiple Sclerosis (clinicaltrials.gov) - Feb 12, 2016
P=N/A, N=50, Active, not recruiting, Sponsor: University at Buffalo
Recruiting --> Active, not recruiting
- Trial completion: Centralized Reading Assessment of Chronic CerebroSpinal Venous Insufficiency (CCSVI) in Patients With Multiple Sclerosis and Other Neurological Diseases (clinicaltrials.gov) - Feb 12, 2016
P=N/A, N=499, Completed, Sponsor: University at Buffalo
Recruiting --> Active, not recruiting Enrolling by invitation --> Completed
- ||| Trial completion: Robotic Arm Assisted Total Knee Arthroplasty (clinicaltrials.gov) - Feb 12, 2016
P=N/A, N=100, Completed, Sponsor: MAKO Surgical Corp.
Enrolling by invitation --> Completed Withheld --> Completed
- || Copaxone 3TW (glatiramer acetate three times a week) / Teva
Trial primary completion date: Evaluate the Effect of Switching From Daily Injections of 20mg Glatiramer Acetate (GA) to 40mg GA Three Times a Week in Subjects With Relapsing-remitting Multiple Sclerosis (clinicaltrials.gov) - Feb 12, 2016
P=N/A, N=150, Enrolling by invitation, Sponsor: University at Buffalo
Withheld --> Completed Trial primary completion date: Jul 2015 --> Apr 2016
- Trial completion: NEURODIAB1: Assessment of the Neurovascular Microcirculatory Response in Diabetes Type 1 Patients (clinicaltrials.gov) - Feb 12, 2016
P=N/A, N=40, Completed, Sponsor: University Hospital, Angers
Trial primary completion date: Jul 2015 --> Apr 2016 Recruiting --> Completed
- Trial primary completion date, Compliance, Adherence: ESSTIM: Prospective Evaluation of Decision and Compliance With Antimalarials in Patients With Systemic Lupus (clinicaltrials.gov) - Feb 11, 2016
P=N/A, N=250, Recruiting, Sponsor: University Hospital, Lille
Recruiting --> Completed Trial primary completion date: Dec 2015 --> Dec 2016
- mycophenolate mofetil / Generic mfg., azathioprine / Generic mfg.
Trial primary completion date: Retinoids in ANCA Small Vessel Vasculitis: Silencing Autoantigens (clinicaltrials.gov) - Feb 11, 2016
P2, N=0, Withdrawn, Sponsor: University of North Carolina, Chapel Hill
Trial primary completion date: Dec 2015 --> Dec 2016 Trial primary completion date: Feb 2015 --> Dec 2013
- ||||||| Actemra IV (tocilizumab) / Roche, JW Pharma
Trial completion: A Study of RoActemra/Actemra (Tocilizumab) in Patients With Active Systemic Juvenile Idiopathic Arthritis (JIA) (clinicaltrials.gov) - Feb 11, 2016
P3, N=112, Completed, Sponsor: Hoffmann-La Roche
Trial primary completion date: Feb 2015 --> Dec 2013 Active, not recruiting --> Completed
- | Trial completion: Lipoic Acid for Secondary Progressive Multiple Sclerosis (MS) (clinicaltrials.gov) - Feb 11, 2016
P2/3, N=56, Completed, Sponsor: VA Office of Research and Development
Active, not recruiting --> Completed Active, not recruiting --> Completed
- ||| Prolastin-C (human alpha1-proteinase inhibitor IV) / Grifols, OrphanPacific
Enrollment closed: Study of Human Plasma-Derived Alpha1-Proteinase Inhibitor in Subjects With New-Onset Type 1 Diabetes Mellitus (clinicaltrials.gov) - Feb 11, 2016
P2, N=76, Active, not recruiting, Sponsor: Grifols Therapeutics Inc.
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- |||| Xeljanz (tofacitinib) / Pfizer
Clinical: Long-Term Effectiveness And Safety Of CP-690,550 For The Treatment Of Rheumatoid Arthritis (clinicaltrials.gov) - Feb 11, 2016
P2, N=4385, Recruiting, Sponsor: Pfizer
Recruiting --> Active, not recruiting Active, not recruiting --> Recruiting
- |||| Plivensia (sirukumab) / J&J
Trial primary completion date: A Study of CNTO 136 (Sirukumab), a Human Anti-IL-6 Monoclonal Antibody, Administered Subcutaneously, in Patients With Active Rheumatoid Arthritis Despite Anti-TNF-Alpha Therapy (SIRROUND-T) (clinicaltrials.gov) - Feb 11, 2016
P3, N=879, Active, not recruiting, Sponsor: Janssen Research & Development, LLC
Active, not recruiting --> Recruiting Trial primary completion date: Dec 2015 --> Mar 2015
- Trial primary completion date: PLASMASEP: Plasma Exchanges in Multiple Sclerosis (MS) Relapses (clinicaltrials.gov) - Feb 11, 2016
P3, N=80, Recruiting, Sponsor: University Hospital, Bordeaux
Trial primary completion date: Dec 2015 --> Mar 2015 Trial primary completion date: Jan 2016 --> Jan 2017
- |||| Cimzia (certolizumab pegol) / Astellas, UCB
Trial completion: Study to Assess the Short- and Long-term Efficacy of Certolizumab Pegol Plus Methotrexate Compared to Adalimumab Plus Methotrexate in Subjects With Moderate to Severe Rheumatoid Arthritis (RA) Inadequately Responding to Methotrexate (clinicaltrials.gov) - Feb 11, 2016
P4, N=916, Completed, Sponsor: UCB Pharma SA
Trial primary completion date: Jan 2016 --> Jan 2017 Active, not recruiting --> Completed
- teriflunomide / Generic mfg.
New trial: Teriflunomide Male Transmission Study (clinicaltrials.gov) - Feb 10, 2016
P=N/A, N=40, Recruiting, Sponsor: Griffin Hospital
- ||| Actemra IV (tocilizumab) / Roche, JW Pharma
New trial: A Comparative Study to Observe the Effect of Concomitant Use of Corticosteroid Treatment in Rheumatoid Arthritis (RA) Participants Who Are Treated With a Tumor Necrosis Factor (TNF) Inhibitor or Tocilizumab (TCZ) as Their Second Biological Treatment. (clinicaltrials.gov) - Feb 10, 2016
P=N/A, N=200, Not yet recruiting, Sponsor: Hoffmann-La Roche
- ||| Trial completion: REACTIV: Randomised Controlled Clinical Trial of Cognitive Rehabilitation in Multiple Sclerosis (clinicaltrials.gov) - Feb 10, 2016
P=N/A, N=65, Completed, Sponsor: University Hospital, Bordeaux
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Trial completion, Enrollment change, Trial primary completion date: Effect of a Medium Chain Triglyceride Supplemented Diet on Cognitive Function and Brain Activation in Type 1 Diabetes. (clinicaltrials.gov) - Feb 9, 2016
P=N/A, N=12, Completed, Sponsor: Yale University
Active, not recruiting --> Completed Recruiting --> Completed | N=30 --> 12 | Trial primary completion date: Aug 2014 --> Aug 2015
- Enrollment open, Trial initiation date, Trial primary completion date: SOCOG-MS: Study of Social Cognition by Morphological and Functional Imaging in Multiple Sclerosis Patients (clinicaltrials.gov) - Feb 9, 2016
P=N/A, N=35, Recruiting, Sponsor: University Hospital, Bordeaux
Recruiting --> Completed | N=30 --> 12 | Trial primary completion date: Aug 2014 --> Aug 2015 Not yet recruiting --> Recruiting | Initiation date: Feb 2015 --> Nov 2015 | Trial primary completion date: Feb 2016 --> Nov 2016
- | insulin peglispro (LY2605541) / Eli Lilly
Trial completion: A Study of How Insulin Peglispro (LY2605541) and Insulin Glargine Affect the Breakdown of Fat and Sugar in Type 1 Diabetics (clinicaltrials.gov) - Feb 9, 2016
P1, N=32, Completed, Sponsor: Eli Lilly and Company
Not yet recruiting --> Recruiting | Initiation date: Feb 2015 --> Nov 2015 | Trial primary completion date: Feb 2016 --> Nov 2016 Recruiting --> Completed
- Enrollment open: Post-transfusion Platelet Count (clinicaltrials.gov) - Feb 9, 2016
P=N/A, N=65, Recruiting, Sponsor: Region Skane
Recruiting --> Completed Not yet recruiting --> Recruiting
- Tavneos (avacopan) / Kissei, Amgen, Otsuka
Enrollment closed, Enrollment change: Open-Label Study to Evaluate Safety and Efficacy of CCX168 in Subjects With IGA Nephropathy on Stable RAAS Blockade (clinicaltrials.gov) - Feb 9, 2016
P2, N=5, Active, not recruiting, Sponsor: ChemoCentryx
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting | N=20 --> 5
- Preclinical, Trial primary completion date: [18F]PBR111 and Microglial Activation in Multiple Sclerosis (clinicaltrials.gov) - Feb 9, 2016
P2, N=50, Terminated, Sponsor: GlaxoSmithKline
Recruiting --> Active, not recruiting | N=20 --> 5 Trial primary completion date: Nov 2012 --> Mar 2013
- ||| Enrollment open: Long Term CGM Treatment in Patients With Type 1 Diabetes Treated With Insulin Injections (clinicaltrials.gov) - Feb 8, 2016
P=N/A, N=130, Enrolling by invitation, Sponsor: Vastra Gotaland Region
Trial primary completion date: Nov 2012 --> Mar 2013 Not yet recruiting --> Enrolling by invitation
- New trial: GLUCAL: Impact of Food Carbohydrate and Insulin Dose Computing by on Smart Phone on Glucose Control in Patients With Diabetes (clinicaltrials.gov) - Feb 8, 2016
P=N/A, N=30, Recruiting, Sponsor: University Hospital, Montpellier
- | spebrutinib (CC-292) / BMS
Enrollment closed, Enrollment change: Efficacy and Safety Study of CC-292 Versus Placebo as Co-therapy With Methotrexate in Active Rheumatoid Arthritis (clinicaltrials.gov) - Feb 6, 2016
P2, N=47, Active, not recruiting, Sponsor: Celgene Corporation
Not yet recruiting --> Enrolling by invitation Recruiting --> Active, not recruiting | N=80 --> 47
- ||||||| Benlysta (belimumab) / GSK
Trial completion: BLISS-SC: A Study of Belimumab Administered Subcutaneously in Subjects With Systemic Lupus Erythematosus (SLE) (clinicaltrials.gov) - Feb 6, 2016
P3, N=839, Completed, Sponsor: Human Genome Sciences Inc., a GSK Company
Recruiting --> Active, not recruiting | N=80 --> 47 Active, not recruiting --> Completed
- | dimethyl fumarate / Generic mfg.
New P4 trial, IO biomarker: Mechanisms of Action of Dimethyl Fumarate (Tecfidera) in Relapsing MS (clinicaltrials.gov) - Feb 5, 2016
P4, N=45, Recruiting, Sponsor: Washington University School of Medicine
- |||||| Kesimpta (ofatumumab subcutaneous) / Novartis, Genmab
Enrollment open: Long-Term Extension Study of Ofatumumab in Subjects With Pemphigus Vulgaris (clinicaltrials.gov) - Feb 5, 2016
P3, N=110, Recruiting, Sponsor: GlaxoSmithKline
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- |||| Solymbic (adalimumab biosimilar) / Amgen, Amjevita (adalimumab biosimilar) / Amgen, Daiichi Sankyo
Trial primary completion date: OLE Study: Long-term Safety and Efficacy of ABP 501 in Subjects With Moderate to Severe Rheumatoid Arthritis (clinicaltrials.gov) - Feb 4, 2016
P3, N=467, Active, not recruiting, Sponsor: Amgen
Not yet recruiting --> Recruiting Trial primary completion date: Sep 2016 --> Apr 2016
- || Orencia (abatacept) / BMS
Trial initiation date, Trial primary completion date: ReACTION: Impact and Use of Abatacept IV for Rheumatoid Arthritis in Real Life Setting (clinicaltrials.gov) - Feb 4, 2016
P=N/A, N=220, Not yet recruiting, Sponsor: Bristol-Myers Squibb
Trial primary completion date: Sep 2016 --> Apr 2016 Initiation date: Jun 2011 --> Sep 2016 | Trial primary completion date: Dec 2015 --> Jan 2018
- || Venoglobulin-IH (polyethylene glycol treated human immunoglobulin G) / Mitsubishi Tanabe
Trial completion: Efficacy and Safety Study of GB-0998 for Guillain-Barré Syndrome (clinicaltrials.gov) - Feb 4, 2016
P3, N=21, Completed, Sponsor: Japan Blood Products Organization
Initiation date: Jun 2011 --> Sep 2016 | Trial primary completion date: Dec 2015 --> Jan 2018 Recruiting --> Completed
- New P2 trial: Progressive Muscle Relaxation Effect on Sleep Quality, Depression and Stress in People With Multiple Sclerosis (clinicaltrials.gov) - Feb 4, 2016
P2, N=40, Completed, Sponsor: Federal University of Espirito Santo
- Trial primary completion date: Carbohydrate Estimation Supported by the GoCARB System (clinicaltrials.gov) - Feb 4, 2016
P=N/A, N=20, Recruiting, Sponsor: University Hospital Inselspital, Berne
Recruiting --> Completed Trial primary completion date: Dec 2015 --> Dec 2016
- ianalumab (VAY736) / MorphoSys, Novartis
Enrollment change, Trial withdrawal: Study of Pharmacodynamic Effects of VAY736 in Patients With Primary Sj (clinicaltrials.gov) - Feb 4, 2016
P1/2, N=0, Withdrawn, Sponsor: Novartis Pharmaceuticals
Trial primary completion date: Dec 2015 --> Dec 2016 N=25 --> 0 | Not yet recruiting --> Withdrawn
- Enrollment change: CARBEX1: Impact of Physical Activity on Blood Glucose Stability and Energy Stores in Individuals With Type 1 Diabetes (clinicaltrials.gov) - Feb 4, 2016
P=N/A, N=27, Enrolling by invitation, Sponsor: University Hospital Inselspital, Berne
N=25 --> 0 | Not yet recruiting --> Withdrawn N=22 --> 27
- Kevzara (sarilumab) / Asahi Kasei, Regeneron, Sanofi
Enrollment closed, Monotherapy: Single-dose Study to Describe the Safety of Sarilumab and Tocilizumab in Patients With Rheumatoid Arthritis (clinicaltrials.gov) - Feb 4, 2016
P1, N=30, Active, not recruiting, Sponsor: Sanofi
N=22 --> 27 Recruiting --> Active, not recruiting
- ||| Trial completion, HEOR: Factors Associated With Biologic DMARD Switching (clinicaltrials.gov) - Feb 4, 2016
P=N/A, N=4099, Completed, Sponsor: Bristol-Myers Squibb
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- ||| Orencia (abatacept) / BMS
Enrollment closed, P4 data, Combination therapy: Abatacept Post-marketing Clinical Study in Japan (clinicaltrials.gov) - Feb 4, 2016
P4, N=405, Active, not recruiting, Sponsor: Bristol-Myers Squibb
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- Trial initiation date, Trial primary completion date: Task-oriented Circuit Training Combined With Cerebellar tDCS in Multiple Sclerosis Subjects (clinicaltrials.gov) - Feb 3, 2016
P2, N=30, Not yet recruiting, Sponsor: University Hospital of Ferrara
Recruiting --> Active, not recruiting Initiation date: Apr 2015 --> May 2016 | Trial primary completion date: Dec 2015 --> Dec 2016
- | Phase classification, Enrollment change, Trial initiation date, Trial primary completion date: Laser Therapy to Treat the Dry Mouth of Sjogren's Syndrome (clinicaltrials.gov) - Feb 3, 2016
P3, N=72, Recruiting, Sponsor: Federal University of São Paulo
Initiation date: Apr 2015 --> May 2016 | Trial primary completion date: Dec 2015 --> Dec 2016 Phase classification: P2 --> P3 | N=34 --> 72 | Initiation date: Jan 2014 --> May 2014 | Trial primary completion date: Jun 2014 --> Jun 2016
- ||| Orencia (abatacept) / BMS
Trial completion: Patient-Reported Efficacy of Subcutaneous (SC) Abatacept in Rheumatoid Arthritis (RA) - South Africa (clinicaltrials.gov) - Feb 3, 2016
P=N/A, N=69, Completed, Sponsor: Bristol-Myers Squibb
Phase classification: P2 --> P3 | N=34 --> 72 | Initiation date: Jan 2014 --> May 2014 | Trial primary completion date: Jun 2014 --> Jun 2016 Active, not recruiting --> Completed
- |||||| Cyltezo (adalimumab biosimilar) / Boehringer Ingelheim
Enrollment open: VOLTAIRE-RAext: Long-term Assessment of Safety and Efficacy of BI 695501 in Patients With Rheumatoid Arthritis (clinicaltrials.gov) - Feb 3, 2016
P3, N=400, Recruiting, Sponsor: Boehringer Ingelheim
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- |||| Cyltezo (adalimumab biosimilar) / Boehringer Ingelheim
Enrollment open: Assessment of the Handling Experience With the BI 695501 Autoinjector in Patients With Rheumatoid Arthritis Followed by an Extension Phase Using BI 695501 Prefilled Syringe (clinicaltrials.gov) - Feb 3, 2016
P2, N=70, Recruiting, Sponsor: Boehringer Ingelheim
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- | Tavneos (avacopan) / Kissei, Amgen, Otsuka
Enrollment closed: Clinical Trial to Evaluate Safety and Efficacy of CCX168 in ANCA-Associated Vasculitis (clinicaltrials.gov) - Feb 3, 2016
P2, N=42, Active, not recruiting, Sponsor: ChemoCentryx
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- Trial completion: Wii FIT Balance Board to Recording Balance Parameters in Multiple Sclerosis Subjects (clinicaltrials.gov) - Feb 3, 2016
P=N/A, N=40, Completed, Sponsor: University Hospital of Ferrara
Recruiting --> Active, not recruiting Recruiting --> Completed
- ||||| Actemra SC (tocilizumab SC) / Roche, Halozyme
Enrollment closed: A Study of Subcutaneous (SC) Tocilizumab (RoActemra/Actemra) in Participants With Active Rheumatoid Arthritis (RA) and Inadequate Response to Disease-Modifying Anti-Rheumatic Drugs (DMARDs) (clinicaltrials.gov) - Feb 3, 2016
P3, N=134, Active, not recruiting, Sponsor: Hoffmann-La Roche
Recruiting --> Completed Recruiting --> Active, not recruiting
- |||| mavrilimumab (KPL-301) / Kiniksa
Trial completion, Trial initiation date: A Long Term Safety Study of Mavrilimumab in Adult Subjects With Rheumatoid Arthritis (clinicaltrials.gov) - Feb 3, 2016
P2, N=409, Completed, Sponsor: MedImmune LLC
Recruiting --> Active, not recruiting Active, not recruiting --> Completed | Initiation date: Aug 2012 --> Dec 2002
- Xeljanz (tofacitinib) / Pfizer
Clinical: Pharmacokinetics Of CP-690,550 In Pediatric Patients With Juvenile Idiopathic Arthritis (JIA) (clinicaltrials.gov) - Feb 2, 2016
P1, N=26, Completed, Sponsor: Pfizer
Active, not recruiting --> Completed | Initiation date: Aug 2012 --> Dec 2002 N=21 --> 26
- ||| Actemra IV (tocilizumab) / Roche, JW Pharma
Enrollment open, Enrollment change: U-Act-After: An Observational Study on Long-Term Efficacy of Tight Control RoActemra/Actemra (Tocilizumab) and/or Methotrexate in Patients With Early Rheumatoid Arthritis Who Have Participated in the U-Act-Early Study (ML22497) (clinicaltrials.gov) - Feb 2, 2016
P=N/A, N=300, Recruiting, Sponsor: Hoffmann-La Roche
N=21 --> 26 Active, not recruiting --> Recruiting | N=201 --> 300